HIV molecular immunology database

 

Patient Detail

Patient Code 3043 (RV305# 3043)
Patient Sex
Risk Factor Other (OT)
Infection Country
Infection City
Infection Year
HLA Type
Patient Ethnicity Thai
Progression
Species human
Patient Note HIV-uninfected subject 3043 was part of the RV144 vaccine trial in Thailand and then the followup RV305 Group 1 vaccine boost (ALVAC-HIV plus AIDSVAX B/E gp120) 6-8 years later. Post-RV144, 106 mAbs were isolated of which 10 had long HCDR3s and mean VH nucleotide % mutation was 3.29. Post-RV305, 61 mAbs were isolated of which 16 had long HCDR3s and mean VH nucleotide % mutation was 7.27. 9 gp120-reactive B cell clonal lineages were common to both post-RV144 and -RV305 plasma, of which 2 (DH686 and DH576) had long HCDR3s. [Easterhoff2017 PMID 28235027]
CTL CD8+ Records
T-Helper CD4+ Records
Antibody Records DH576 (3837), DH576.1 (3838), DH576.2 (3839), DH577 (3840)
Sequence Database Patient ID Record
Questions or comments? Contact us at immuno@lanl.gov
 
Managed by Triad National Security, LLC for the U.S. Department of Energy’s National Nuclear Security Administration
Copyright © 2022 Triad National Security, LLC | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health